Figure 3
From: Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines
CYP2S1 knockdown elevate resistance of p53+/+HCT116 cells to oxaliplatin treatment in vitro.
CYP2S1 knockdown conferred cell survival advantage after oxaliplatin treatment to cells harboring wild-type p53 but not to isogenic cells lacking p53. Cells were treated with the shNT (denotes non-targeting control shRNA) or CYP2S1 shRNA, respectively. Cell viability after Oxaliplatin (20 μM) treatment was determined by the CCK8 assay. (A,B) p53+/+ HCT116 CYP2S1 knockdown cells are highly resistant to oxaliplatin treatment. Reduced CYP2S1 protein expression in cells was confirmed by Western blot, one of three representative experiments is shown. (C,D) Total RNA was extracted and the mRNA levels of the CYP2S1 gene were analyzed in qRT–PCR analysis. Results are of the average from three experiments. Data are represented as mean ± s.d., *p < 0.05, **p < 0.01.
